savolitinib,tremelimumab,durvalumab
orpathys,pfizer,astrazeneca,medsir,hutchmed
['improve', 'calypso', 'tremelimumab', 'renal,(-adrenal)', 'durvalumab', 'medsir']
dr. thomas powles from gives an update on the #calypso showing that savolitnib alone or in combo with durvalumab didn't meet predefined activity levels for advanced clear cell renal cancer. addition of tremelimumab to durvalumab didn't improve efficacy.
#asco22 
Bring your idea to life?? 
Creating successful IITs & optimizing drug development ?? 
Medica Scientia Innovation Research
 ????&????
https://t.co/yp3O5Lylqc